Janux Therapeutics Showcases Advancements In TRACTr, TRACIr, And ARM Platforms Ahead Of 2026 Trials At R&D Day Webcast

Author: Benzinga Newsdesk | July 24, 2025 03:28pm

• PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses.
• TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential.
• CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026.
• Webcast to be held today at 1:30 PM PT.

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, will host its virtual R&D Day today at 1:30 PM PT. The event will highlight the company's continued momentum in advancing its novel immunotherapy platforms—TRACTr and TRACIr, as well as ARM—designed to address significant unmet needs in oncology and autoimmune diseases.

Posted In: JANX